Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Samantha I. Liang; Zoe Quandt; Sara Wienke; Jing Wang; Sean Gordon; Reagan M. Barnett; Jude Masannat; Kyle Chang; Carin R. Espenschied; Katie Quinn; Kimberly C. Banks; Enjun Yang; John E. Connolly

doi:10.1158/2767-9764.29948090

August 20, 2025Open Access

Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Tumor fraction change is predictive of outcomes in patients undergoing immune checkpoint inhibitors.
Baseline detection of tumor fraction appears to have prognostic significance, guiding future interventions.
Assessment of tumor fraction change in a real-world setting can offer insights into clinical benefits of treatment.
Findings may enable better patient selection for immune checkpoint inhibitor therapy in oncological practice.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis reveals that tumor fraction change predicts outcomes in pan-cancer patients, suggesting a potential biomarker for treatment efficacy.

Abstract

Baseline TF detection is prognostic but TF change is predictive of outcome

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc779 https://doi.org/10.1158/2767-9764.29948090

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers